Company / PP&E (Net)
RECURSION PHARMACEUTICALS, INC. PP&E (Net) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$103.9M
FY2025
5-year range
$64.7M / $141.1M
FY2021-FY2025
Trend
-26.3%
vs FY2024
Sector context
#46 of 193
Health Care
What the data says
RECURSION PHARMACEUTICALS, INC.'s pp&e (net) of $104M is higher than 76% of companies in the Health Care sector (FY2025). PP&E (Net) has fluctuated over the past 6 years, ranging from $26M in FY2020 to $141M in FY2024.
Based on SEC 10-K filings.
$104M in FY2025 with a 5-year CAGR of +32.0%. Top quartile in the Health Care sector.
Improved from $87M to $104M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +5.6%
- 5-Year CAGR
- +32.0%
- 10-Year CAGR
- -
Sector benchmark
Top 24% in Health CareTop 24% of 193This company $103.9M Sector average $777.6M
▼
-86.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +32.0%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 26.3% year-over-year.
- Ranks #46 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.80 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $103.9M | -26.3% |
| FY2024 | $141.1M | +63.1% |
| FY2023 | $86.5M | -1.9% |
| FY2022 | $88.2M | +36.3% |
| FY2021 | $64.7M | +149.3% |
| FY2020 | $26.0M | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026